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In our study we wanted to elucidate a time frame for in vivo optical imaging of the therapeutic efﬁcacy of
photodynamic therapy (PDT) by using a multiplexed imaging approach for detecting apoptosis and
vascularization. The internalization of the photosensitizer Foslip into tongue-squamous epithelium
carcinoma cells (CAL-27) was examined in vitro and in vivo. For detecting apoptosis, annexin V was
covalently coupled to the near-infrared dye DY-734 and the spectroscopic properties and binding afﬁnity
to apoptotic CAL-27 cells were elucidated. CAL-27 tumor bearing mice were treated with PDT and
injected 2 days and 2 weeks thereafter with DY-734-annexin V. PDT-induced changes in tumor vascu-
larization were detected with the contrast agent IRDye 800CW RGD up to 3 weeks after PDT. A peri-
nuclear enrichment of Foslip could be seen in vitro which was reﬂected in an accumulation in CAL-27
tumors in vivo. The DY-734-annexin V (coupling efﬁciency 30e50%) revealed a high binding afﬁnity to
apoptotic compared to non-apoptotic cells (17.2% vs. 1.2%) with a KD-value of 20 nM. After PDT-treatment,
the probe showed a signiﬁcantly higher (p <0.05) contrast in tumors at 2 days compared to 2 weeks after
therapy (2e8 h post injection). A reduction of the vascularization could be detected after PDT especially
in the central tumor areas. To detect the therapeutic efﬁcacy of PDT, a multiplexed imaging approach is
necessary. A detection of apoptotic cells is possible just shortly after therapy, whereas at later time points
the efﬁcacy can be veriﬁed by investigating the vascularization.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Non-invasive optical imaging of molecular processes in vivo is a
promising technology for the therapeutic monitoring in personal-
ized medicine [1]. Among the different oncologic therapeutic
approaches available so far, like chemotherapy or radiation,
photodynamic therapy (PDT) of tumors uses light along with the
administration of a photosensitizing agent as a therapeutic tool [2].
In effect, a direct cell death occurs as a result of the production of
reactive oxygen species. Besides the induction of apoptosis in tu-
mor cells, the vasculature is damaged, which leads to anax: þ49 3641 9325922.
x: þ49 3641 9325922.
(K. Haedicke), Ingrid.Hilger@
Ltd. Open access under CC BY-NC-ND licenundersupply of the tumor with nutrients and ultimately de-
termines the therapeutic success [3,4].
A central process in the effective elimination of tumor cells is
apoptosis [5]. Cells externalize phosphatidylserine on their outer
membrane leaﬂet in the early phase of apoptosis [6]. This process
makes the phospholipid accessible to targetedprobeswhere it serves
as target for detecting apoptotic cells. Typical examples of phos-
phatidylserine targeted probes are annexin V based probes [7,8].
In recent studies the use of different modiﬁed 99mTc-labeled
annexin V for single photon emission computed tomography
(SPECT) or autoradiography have been reported [9,10]. Also tar-
geting of apoptotic cells with biotinylated annexin V followed by
administration of 64Cu-labeled streptavidin allowed apoptotic tis-
sues to be imaged by positron emission tomography (PET) [11].
Although the utilization of near-infrared ﬂuorescent (NIRF) probes
for the in vivo optical imaging of apoptosis is also very suitable and
non-invasive, only few data demonstrated the use of NIRF probes in
imaging apoptosis. After conjugation of annexin V to Cy5.5, such
probes were shown to image the effect of cyclophosphamide
chemotherapy on Lewis lung carcinoma at 24 h post treatmentse. 
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Fig. 1. Schematic presentation of the in vivo experimental design for imaging tumor vascularization and apoptotic cells after PDT. The time points demonstrate injection of the
respective probes in PDT-treated and non-PDT-treated mice. y: animals were sacriﬁced.
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imaging was demonstrated at day 4 of an anti-angiogenic therapy
because of a signiﬁcant breakdown of the vasculature [14]. These
reports reveal that the use of multiplexed methods which enable
simultaneous detection of apoptosis and vascularization are inev-
itable in the reliablemonitoring of therapeutic efﬁcacy. Apoptosis is
important for detecting cell death as a consequence of the thera-
peutic efﬁcacy of PDT and vascularization also veriﬁes probe
accessibility. The advantage of ﬂuorescence optical imaging over
PET is that it allows multiplexed approaches by means of a simul-
taneous detection of several ﬂuorescent probes which differ in their
emission maxima.
In this study, we therefore sought to elucidate the appropriate
time frame for in vivo imaging of the therapeutic efﬁcacy of PDT via
the use of a multiplexed imaging approach which addresses both
the phosphatidylserine molecules on cells at the tumor region as
well as the expression of avb3 integrin on the surface of prolifer-
ating endothelial cells as a marker for vascularization. We ﬁrst
examined the internalization of the photosensitizer formulation
Foslip into the tumor cells to corroborate a basic prerequisite for a
successful PDT. Then, the binding afﬁnity of a self-designed NIRF
annexin V probe to the cells was evaluated in vitro. We subse-
quently used the probe for detection of apoptosis in mice xeno-
grafts together with an integrin-targeted probe to assess the level
of vascularization at deﬁned time points after PDT.
2. Materials and methods
2.1. Cells and animals
Tongue-squamous epithelium carcinoma cells (CAL-27, DSMZ, Braunschweig,
Germany) were cultured in DMEM-GlutaMAX (Gibco, Darmstadt, Germany)
containing 10% FBS, at 37 C in a humidiﬁed 5% CO2 atmosphere. In vivo experiments
were carried out with female athymic nude-Foxn1nu mice (20e25 g, Harlan Labo-
ratories GmbH, Venray, The Netherlands). During experimentation, the animals
were anesthetized with isoﬂuorane (Actavis, Munich, Germany). All procedures
were approved by the regional animal committee and were in accordance with
international guidelines on the ethical use of animals. Mice were housed under
standard conditions with food and water ad libitum.
2.2. In vitro characterization and biodistribution of the photosensitizer formulation
Foslip
The photosensitizer formulation Foslip (liposomal formulation of meta tetra-
hydroxyphenyl chlorine e mTHPC) was provided by biolitec research GmbH (Jena,Germany) as a lyophilized powder that was reconstituted with sterile water to
1.5 mg mTHPC ml1. To verify the spectroscopic features of Foslip, both the ab-
sorption and the emission spectrum were determined via spectrophotometry and
spectroﬂuorometry.
To investigate the cellular uptake of Foslip, CAL-27 cells were incubated with
50 mM of the photosensitizer for 24 h. Nuclei were counterstained with 0.2 mg/ml
Hoechst-33258 (Applichem, Darmstadt, Germany). Cells were analyzed using a
confocal laser scanning microscope (LSM 510 Meta, Zeiss, Jena, Germany).
The effect of laser treatment alone was investigated by illuminating CAL-27 cells
in vitro with different light dosages up to 100 J/cm2 and measuring caspase 3/7
activity (important enzyme of apoptosis) as well as cell viability by XTT assay at 24 h
after illumination.
To study the biodistribution of Foslip, 2  106 CAL-27 cells in Matrigel (BD,
Heidelberg, Germany) were injected subcutaneously into 8 mice. When the tumors
reached a diameter of approximately 5 mm, mice were injected with Foslip (50 mg/
kg, n ¼ 5). 3 mice (control group) were left without any photosensitizer to monitor
autoﬂuorescence of the organs. 24 h post injection, the animals were sacriﬁced and
the ﬂuorescence intensity of the tumors and organs was measured ex vivo using the
Maestro in vivo ﬂuorescence imaging system (excitation ﬁlter: 570e610 nm,
emission ﬁlter: 645 nm longpass, CRi Inc., Woburn, MA, USA). The generated com-
posite spectral data were unmixed into the spectrum of the autoﬂuorescence of the
mice and the spectrum of Foslip. For semiquantitative analysis, regions of interest
(ROIs) were drawn over the spectrally unmixed image of tumor and organs. For
every ROI an averaged ﬂuorescence signal was determined, which represents the
area under the curve of the unmixed Foslip spectrum. Average counts were
normalized to exposure time and pixel number.
2.3. Labeling of annexin V with the NIRF dye DY-734
To detect apoptotic cells after PDT via ﬂuorescence optical imaging, annexin V
(Abcam, Cambridge, UK) was covalently coupled to the near-infrared dye DY-734
(using a NHS-ester derivative, abs: 736 nm, em: 759 nm, Dyomics GmbH, Jena,
Germany): 0.1 mg annexin V was mixed with DY-734-NHS in coupling buffer
(100 mM NaHCO3, 500 mM NaCl, pH 8) and incubated for 2 h (22 C and 900 rpm).
Unbound dye molecules were separated by ultraﬁltration on a 10 kDa amicon col-
umn (Merck Millipore, Billerica, MA, USA). After washing 3 times with PBS, the
ﬂuorescent annexin V probe (DY-734-annexin V) was eluted and the success of
coupling as well as the annexin V to DY-734 ratio were determined spectroscopi-
cally. Hereto, the absorption maxima of both the protein and the dye were used and
the ratio was determined via the LamberteBeer law.
2.4. Determination of the binding afﬁnity of DY-734-annexin V to apoptotic cells
To induce apoptosis, CAL-27 cells were incubatedwith etoposide (30 mM, Sigmae
Aldrich, Munich, Germany) for 24 h. Afterward, the cells were split into 4 different
groups and stained as follows: 1) native control (without staining), 2) apoptosis
(staining with 10 mg/ml DY-734-annexin V), 3) necrosis (staining with propidium
iodide (PI), Annexin-V-FLUOS Staining Kit, Roche, Grenzach, Germany), and 4)
apoptosis and necrosis (staining with DY-734-annexin V and PI). The same proce-
dure was applied to cells without etoposide to control the autoﬂuorescence and the
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Fig. 2. Characterization of Foslip and cellular uptake of Foslip by CAL-27 cells. (A) Absorption and emission spectrum of Foslip in sterile water. (B) Uptake of Foslip into CAL-27
cells. Cells with (left) and without (right) Foslip incubation. Blue: cell nuclei stained with Hoechst. Red: Foslip. Bar: 50 mm. (C) Biodistribution of Foslip in CAL-27 tumor bearing
mice 24 h after intravenous administration (black bars, n ¼ 5), in comparison to mice of the native group without Foslip administration (autoﬂuorescence of the organs, white bars,
n ¼ 3). (*p <0.05). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
K. Haedicke et al. / Biomaterials 34 (2013) 10075e10083 10077unspeciﬁc binding to non-apoptotic cells. Flow cytometry was carried out using a
FC500 ﬂow cytometer (Beckman Coulter, Krefeld, Germany). The differently treated
cells were also examined under an Olympus BX 50 microscope (Olympus
Deutschland GmbH, Hamburg, Germany) to see changes within the morphology.
To elucidate cellular localization of DY-734-annexin V, etoposide (10 mM)
induced apoptotic CAL-27 cells were incubated with the optical probe (1 mM) for
10 min. Afterward, the cell membrane was stained using wheat germ agglutinin
(WGA) Alexa 555 (10 mg/ml, Invitrogen, Darmstadt, Germany). Nuclei were coun-
terstained with 0.2 mg/ml Hoechst 33258. Stained cells were imaged using an EVOS
ﬂuorescence microscope (AMG, Bothell, WA, USA).
To quantitatively characterize the binding afﬁnity of the optical probe, etoposide
(30 mM) induced apoptotic CAL-27 cells were incubated with increasing concentra-
tions of DY-734-annexin V (0 up to 60 nM) for 10 min. Thereafter, the ﬂuorescence
intensity of the pellets was measured with the in vivo ﬂuorescence imaging system.
The dissociation constant KD was calculated indirectly with respect to the ﬂuores-
cence intensity with SigmaPlot 12.0.
The speciﬁcity of the binding of DY-734-annexin V was investigated in vitro by
incubating etoposide induced apoptotic CAL-27 cells with a 10-fold excess (50 nM) or
a 100-fold excess (500 nM) of unlabeled annexin V to block binding sites before
adding 5 nM of DY-734-annexin V. The ﬂuorescence intensity of the cell pellets was
measured with the in vivo ﬂuorescence imaging system.
2.5. PDT of tumors
For in vivo PDT studies, tumors were implanted in 20 mice subcutaneously as
described above. The animals were divided into 2 groups. The PDT-treated group
(n ¼ 10) was injected with Foslip (40 mg/kg weight) and 24 h later the tumors were
illuminated with a 2 W 652 nm Ceralas PDT laser (Biolitec AG, Jena, Germany). The
power density at the tumor was 0.48 W/cm2 and the total light dose 40 J/cm2. The
non-PDT-treated control group (n ¼ 10) was left without photosensitizer and
without laser illumination.
2.6. In vivo imaging of apoptotic cells after PDT
To detect apoptotic cells in the tumors, DY-734-annexin V was injected into the
PDT-treated animal group 2 days (short term therapy monitoring, n ¼ 5) and 2
weeks (long term therapymonitoring, n¼ 5) after therapy (4 nmol/kgweight, Fig.1).
To control for unspeciﬁc enrichment, the probe was injected into the animals of the
non-PDT-treated group (n ¼ 10). The near-infrared ﬂuorescence intensity of the
mice was monitored before probe injection (1 h), and 0, 2e48 h after applicationwith the Maestro system as described above (excitation ﬁlter: 670e710 nm,
emission ﬁlter: 750 nm).
2.7. In vivo imaging of tumor vascularization after PDT
The effect of PDT on tumor vascularizationwas analyzed with the contrast agent
IRDye 800CW RGD Optical Probe (abs: 776 nm, em: 792 nm, LI-COR Biosciences,
Lincoln, NE, USA). This near-infrared imaging agent speciﬁcally targets avb3 integrins
on the surface of endothelial cells in the tumor. The contrast agent was injected into
the PDT-treated animals (n ¼ 10, 40 nmol/kg) directly before PDT, as well as at 1, 2,
and 3 weeks after PDT to image changes of the tumor vascularization over a longer
time period after treatment and to assess its inﬂuence on imaging of apoptosis as
well as probe accessibility (Fig. 1). Contrast agent accumulationwas compared to the
non-PDT-treated group (n ¼ 10). Imaging was carried out by acquisition of near-
infrared ﬂuorescence signals at 24 h after probe injection with the Maestro sys-
tem as described above (excitation ﬁlter: 670e710 nm, emission ﬁlter: 750 nm). The
relative ﬂuorescence intensity was related to the ﬂuorescence of the native mice
(before PDT). Macroscopic changes were depicted by light images of the mice and
tumor volumes were measured using a digital caliper and the equation V ¼ p/
6  (length width  height). The relative tumor volume after therapy was related
to the tumor volume of the native mice (before PDT).
2.8. Biodistribution of DY-734-annexin V and IRDye 800CW RGD
Biodistribution of DY-734-annexin V was compared in the PDT-treated and non-
PDT-treated groups (n ¼ 3 animals/group) 5 days after PDT (3 days after injection,
Fig. 1). All other mice were sacriﬁced 3 weeks after PDT (17 (n ¼ 4) and 8 (n ¼ 10)
days after DY-734-annexin V injection, Fig. 1). Cell nuclei of cryo-frozen tumor slices
were stained with 2 mg/ml Hoechst-33258 and imaged using an EVOS ﬂuorescence
microscope. The biodistribution of IRDye 800CW RGD Optical Probe was analyzed
3 weeks after PDT and 24 h after last IRDye 800CW RGD injection (n ¼ 14). The
ﬂuorescence intensity of the tumors and the organs were measured ex vivo as
described above.
2.9. Statistical analysis
Data are expressed as means  standard error. Statistical signiﬁcance was
analyzed by a two-tailed Student’s t test using SigmaPlot 12.0. If the equal variance
test failed, a ManneWhitney Rank Sum test was run. A p-value of 0.05 or less was
considered statistically signiﬁcant.
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Fig. 4. In vivo detection of PDT-induced apoptotic cells in tumors 2 days after therapy and biodistribution of DY-734-annexin V. (A) Representative composite images of CAL-27
tumor bearing mice injected with DY-734-annexin V 2 days (left column) or 2 weeks (right column) after PDT. (B) Fluorescence contrast (tumor e muscle) of DY-734-annexin
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mean of ﬂuorescence contrast  SEM (n ¼ 5). (*p <0.05) (C) Biodistribution of DY-734-annexin V 5 days after PDT and 3 days after probe injection in PDT-treated (black, n ¼ 3) and
non-PDT-treated (white, n ¼ 3) mice. The images show ex vivo ﬂuorescence signals of the organs. (*p <0.05) (D) Biodistribution of DY-734-annexin V 3 weeks after PDT and 17 days
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images) after PDT and without PDT, respectively. Arrow depicts condensed chromatin which is visible after DNA stain with Hoechst.
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3.1. In vitro and in vivo studies on the photosensitizer Foslip
The absorption spectrum of Foslip showed a peak at 418 nm
and another smaller peak at 650 nm (Fig. 2 A). The emission peak
was at 650 nm after an excitation at 405 nm.
After incubating CAL-27 cells with Foslip, a strong uptake of
the photosensitizer into the cytoplasm could be observed, espe-
cially in the peri-nuclear region (Fig. 2B). Cells without Foslip in-
cubation did not show any background ﬂuorescence.
Laser treatment alone using light dosages up to 100 J/cm2 did
not affect viability of CAL-27 cells in vitro as could be shown via
caspase 3/7 activity and XTT assay (data not shown).
After injection of Foslip into mice, the tumors showed a high
ex vivo ﬂuorescence intensity (0.0026 counts/s) 24 h post injection
just like the other organs (Fig. 2C), such as the lungs (0.0018 counts/
s) and gut (0.0026 counts/s). The heart, spleen, kidney, and liver
featured virtually no ﬂuorescence. The organs of the mice withoutany photosensitizer showed nearly no autoﬂuorescence, with a
signiﬁcantly lower tumor ﬂuorescence (0.00059 counts/s)
compared to mice with Foslip.
3.2. Spectroscopic analysis of DY-734-annexin V
The spectroscopic analysis of DY-734-annexin V showed a high
absorption peak at 718 nm and a smaller protein peak at 280 nm
(Fig. 3A). The DY-734 alone revealed an absorption peak at 715 nm.
The dye to protein ratio was in a range of 0.3 up to 0.5 dye mole-
cules per annexin V protein. Using the in vivo ﬂuorescence imaging
system, DY-734-annexin V revealed a comparable emission spec-
trum to DY-734 alone with a maximum at 750 nm (Fig. 3B).
3.3. Binding afﬁnity of DY-734-annexin V to apoptotic cells
Flow cytometry illustrated a speciﬁc binding of DY-734-annexin
V to apoptotic cells (Fig. 3C). This was evident in the observation
that unstained cells (native) showed little or no autoﬂuorescence,
native
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K. Haedicke et al. / Biomaterials 34 (2013) 10075e1008310080irrespective of etoposide treatment. Apoptotic cells exhibited a
speciﬁc binding of DY-734-annexin V (17.2% of the population) in
comparison to non-apoptotic cells (1.2% of the population). The
incubation of the CAL-27 cells with both DY-734-annexin V and
propidium iodide revealed a clear differentiation between
apoptotic and necrotic cells. Especially after etoposide treatment,
many apoptotic (10.2% of the population) as well as some necrotic
(7.5% of the population) cells could be observed. Altogether, DY-
734-annexin V revealed a high binding capability to phosphati-
dylserine on apoptotic cells, which were induced by etoposide.
There were no differences between untreated and DY-734-annexin
V stained cells (10 mg/ml) in terms of granularity and cell
morphology (data not shown).
Fluorescence microscopy revealed a co-localization of DY-734-
annexin V with WGA-Alexa-555-stained cell membrane in
apoptotic CAL-27 cells (Fig. 3D). In addition, a ﬂuorescence signal of
the probe could also be detected in the cell nuclei.
The estimated dissociation constant of the probe was approxi-
mately 20 nM (Fig. 3E). The speciﬁcity of the binding of DY-734-
annexin V could be shown in vitro by reduced ﬂuorescence after
incubating with a 10-fold excess (ﬂuorescence reduction of 21%) ora 100-fold excess (ﬂuorescence reduction of 89%) of unlabeled
annexin V (data not shown).
3.4. Detection of PDT-induced apoptosis via ﬂuorescence imaging
Among all time points investigated, PDT-induced apoptosis
could be detected only at 2 days after treatment. In this case,
ﬂuorescence signals of DY-734-annexin V were obtained in PDT-
treated tumors in mice with a decrease in signal with time after
injection (Fig. 4A). 48 h after probe application, no optical ﬂuo-
rescence signal could be detected anymore. In contrast to the 2 day
time frame after PDT, at 2 weeks after therapy no accumulation of
the probe could be observed in the tumor over the whole mea-
surement period (0 up to 48 h post injection, Fig. 4A). Macro-
scopically, a stimulated growth of the tumor periphery could be
observed at 2 weeks after PDT.
The corresponding accumulation kinetics at 2 days after therapy
showed a higher contrast (tumor-to-muscle) of DY-734-annexin V
in PDT-treated mice compared to non-PDT-treated mice, especially
as of 4 h post injection (Fig. 4B, black and white bars). This effect
was observed even after 48 h, indicating that the probe is
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PDT-treated ones. The signals in both animal groups decreased
with time, with a faster decrease in non-PDT-treated mice. At 2
weeks after PDT, imaging with DY-734-annexin V revealed lower
signal intensities than at 2 days after PDT (Fig. 4B, gray bars). The
enrichment of DY-734-annexin V in tumors in PDT-treated mice at
2 days after therapy was signiﬁcantly higher (p<0.05) from 2 to 8 h
post injection than in mice which received PDT 2 weeks before
probe injection. Furthermore, the signals were lower in the 2-week
PDT-treated mice than in the non-PDT-treated ones.
Biodistribution analysis of DY-734-annexin V at 5 days after PDT
and 3 days after probe injection showed the highest ﬂuorescence
intensity in the kidneys in PDT-treated as well as in non-PDT-
treated animals (Fig. 4C). The liver of PDT-treated mice revealed a
signiﬁcantly lower (p <0.05) ﬂuorescence signal compared to non-
PDT-treated ones, whereas the spleen showed no signal. 3 weeks
after PDT and 17 days after probe injection the ﬂuorescence signals
in the kidney and liver were comparably low in both animal groups
(Fig. 4D, black and white bars). Also 3 weeks after PDT but 8 days
after probe injection, the ﬂuorescence intensities in these organs
were higher (Fig. 4D, gray bars). Interestingly, the ﬂuorescence
signal in the kidneys of PDT-treated mice was signiﬁcantly lower (p
<0.05) than in the kidneys of non-PDT-treated mice at this time
point. The liver ﬂuorescence was also lower in PDT-treated animals
whereas the spleen revealed no ﬂuorescence.
The stained nuclei of cryo-frozen tumor slices showed an altered
morphology with condensed chromatin especially 5 days after PDT
(Fig. 4E).
3.5. Detection of PDT-induced reduction of the tumor
vascularization via ﬂuorescence imaging
After PDT, a loss of the tumor vascularizationwith time could be
detected via whole body in vivo ﬂuorescence optical imaging.
Initially, the avb3 integrin targeting probe (IRDye 800CW RGD)
showed a homogeneous intratumoral distribution in PDT-treated
animals, whereas with increasing time after PDT, this ﬂuores-
cence signal could only be detected in the outer areas of the tumor
(Fig. 5A). In contrast, non-PDT-treated animals showed homoge-
neous ﬂuorescence signals within the tumors over the whole
experimental period. These observations were substantiated by the
light images of mice, which clearly depicted the macroscopic
destruction of the tumors after PDT in comparison to the tumors
without therapy (Fig. 5A). Simultaneously, an increased growth of
the outer tumor area could be seen at 2 weeks after PDT.
The semiquantitative analysis of the relative ﬂuorescence in-
tensities of the tumors was in agreement with these ﬁndings
(Fig. 5B). The ﬂuorescence intensity of the PDT-treated tumors
decreased as early as 1 week after PDT, remained constant up to 2
weeks after therapy and increased afterward. In comparison, the
relative ﬂuorescence intensity of the non-PDT-treated tumors
showed a constant slight decrease with time. Concomitant to the
decrease of the tumor ﬂuorescence in PDT-treated mice, the tumor
volume of the animals diminished after therapy (Fig. 5C). On the
contrary, in mice without PDT, the tumor volume steadily increased
or remained unchanged with time.
The biodistribution of IRDye 800CW RGD 3 weeks after PDT
and 24 h after the last injection showed the highest ﬂuorescence
signal in the tumors of PDT-treated (0.0044 counts/s) as well as of
non-PDT-treated mice (0.0025 counts/s, Fig. 5D) compared to the
other organs. The ex vivo images of the tumors showed that 3
weeks after PDT the ﬂuorescence which reﬂects accumulation of
the IRDye 800CW RGD probe could only be detected in the outer
areas and not in the central area of the tumor, whereas without PDT
the ﬂuorescence is much higher in the tumor center. Beside thetumors, the lungs, gut, kidneys, and liver revealed ﬂuorescence
signals.4. Discussion
Using an in vivo multiplexed ﬂuorescence optical imaging
approach wewere able to demonstrate that shortly after treatment
a detection of the therapeutic efﬁcacy of PDT was possible via
apoptosis, whereas at longer times after PDT the therapeutic
outcome could only be detected via tumor vascularization.
The photosensitizer formulation Foslip was shown to accu-
mulate in CAL-27 cells with a strong enrichment in the peri-nuclear
region and a diffuse distribution in the cytoplasm and other or-
ganelles. This cellular distribution pattern seems to be typical for
photosensitizers irrespective of the cell line [15,16]. Especially the
Golgi apparatus and the endoplasmic reticulum are the primary
intracellular sites for localization of mTHPC and, to a lesser extent,
also lysosomes and mitochondria [17,18]. The ability of the used
photosensitizer to internalize into target cells fulﬁlls an important
prerequisite for a successful therapy.
In this work Foslip also revealed the ability to accumulate in
CAL-27 xenografts in mice. Since this formulation is characterized
by the encapsulation of the photosensitizer Temoporﬁn in lipo-
somes, the high water solubility allowed for a good accessibility to
the tumor region and a lower formation of aggregates [19]. The
accumulation of the photosensitizer in the other organs, especially
the lung, can be ascribed to the high perfusion of these organs.
Therefore, a well-directed illumination on the tumor will locally
activate the photosensitizing agent and also protect the other or-
gans. In this context, the high enrichment of gut and lungs with the
photosensitizer makes it clear that the treatment of tumors in these
regions is rather challenging.
For in vivo detection of apoptotic cell death after PDT, we suc-
cessfully designed a ﬂuorescence optical annexin V probe. Covalent
coupling of the dye to the annexin V was accomplished, since a
NHS-ester derivative of the DY-734 was used. NHS-esters are
known to be highly reactive with primary amino groups, for
example those which were present on the annexin V protein. This
kind of reaction is widely known to produce an amide bond be-
tween the reactants [20]. Spectroscopic analysis demonstrated the
efﬁcient coupling of the NIRF dye DY-734 to annexin V by the
simultaneous appearance of a protein peak and a dye peak. The
absorption and emission spectra of DY-734 were not altered after
coupling to annexin V. The cellular localization of the probe on the
cell membrane coincided with the localization of phosphati-
dylserine after treating of the cells with the anticancer agent eto-
poside [21]. This means that a speciﬁc detection of a changed
plasma membrane structure is feasible with the annexin V probe.
Moreover, the probe featured a high binding afﬁnity and selectivity
to apoptotic CAL-27 cells. Since the target phosphatidylserine is
highly accessible after externalization to the outer leaﬂet of the
plasma membrane, our probe will mostly bind apoptotic cells. In
contrast, binding to necrotic cells can just occur at later stages,
when themembrane is already disrupted and phosphatidylserine is
accessible at the inner leaﬂet [22]. Additionally, ﬂow cytometry of
apoptotic cells showed that binding to cellular membrane frag-
ments of necrotic cells was comparatively lower than binding to
phosphatidylserine on apoptotic cells. This means that our probe
will mainly detect apoptotic cells in the in vivo situation. The
semiquantitative assessment of the binding afﬁnity of the annexin
V optical probe revealed a dissociation constant of 20 nM. The
determined KD of DY-734-annexin V was nearly of the same
magnitude as corresponding values in other reports [23e27]. This
indicates that the DY-734 dye molecule in the probe did not
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high afﬁnity of the optical probe to apoptotic cells.
Our probe is expected to elicit a low cytotoxic potential. It could
be shown that hemicyanine dyes, such as DY-734, are not cytotoxic
on endothelial andmacrophage cells because of its low lipophilicity
and thus high hydrophilicity [28,29]. The same applies for the
annexin V protein. Annexin is a naturally occurring protein and it
has already beenwidely used in the clinics as target-afﬁne probe in
nuclear medicine applications [22]. As we could show by ﬂow
cytometry, the granularity of the cells after staining with DY-734-
annexin V (10 mg/ml) was comparable to native cells. Further-
more there were no changes of the morphology after staining
compared to untreated cells detectable. For in vivo imaging, a dose
of 4 nmol/kg body weight was applied. This suggests that our op-
tical annexin probe is not cytotoxic and highly biocompatible in the
in vivo situation.
The enrichment of DY-734-annexin V in tumor models in vivo
was seen 2 days after PDT, which is a real effect of the therapy since
we could show that laser treatment alone is safe using in vitro
experiments. It is known that 1 h after PDT deﬁned apoptosis
markers, such as DNA fragments, externalization of phosphati-
dylserine etc., are evident in tumor tissue and increase with time
after treatment [6,30,31]. This means that the annexin V probe
accumulation in tumors at 2 days after PDT coincides with the
known pathobiological mechanisms of apoptosis, particularly with
the alteration of the morphology of cell nuclei. This could be shown
with the chromatin staining of treated tumor tissues. In previous
studies using a radiolabeled annexin V probe, signaling in tumors
were observed only at 2, 4 and 7 h after PDT [9]. The fact that the
annexin probe enrichment was detected at 2 days after PDT pro-
poses that the time frame for a reliable detection of therapeutically-
based apoptotic effects is 48 h post PDT.
The avb3 integrin targeting probe (IRDye 800CWRGD) showed a
homogeneous intratumoral distribution before PDT and only a slight
ﬂuorescence signal in the outer areas of the tumor 2weeks after PDT.
The inability to detect apoptosis with DY-734-annexin V 2 weeks
after PDT is partly attributed to the PDT-induced damage of the tu-
mor vascularization. Consistent with this damage of tumor vessels,
access of the optical probe to apoptotic cells in the tumor is aborted.
The decreased signaling of the RGD probe in tumors at 1 week
after therapy also reﬂects the therapeutic efﬁcacy of PDT. Further-
more, the PDT-based destruction of the blood vessels also results in
a decrease of the tumor volume with time, due to limited avail-
ability of nutrients. This mechanism, which is associated with the
tumor destruction through PDT [32,33], has to the best of our
knowledge, never been monitored via ﬂuorescence optical imaging
over a time frame of 3 weeks. A cytotoxic effect of the IRDye
800CW RGD probe can be excluded because radiolabelled RGD
peptides are already widely used in clinical nuclear medicine [34]
and the cyanine ﬂuorophore IRDye 800CW does not evidence any
pathological effect or toxicity after intravenous or intradermal in-
jection in rats at a much higher concentration of the dye (18 mmol/
kg) [35] compared to our study (40 nmol/kg).
The intratumoral distribution pattern of the IRDye 800CWRGD
probe in PDT-treated tumors was clearly different from non-PDT-
treated tumors. PDT-treated tumors showed ﬂuorescence signals
only in their outer areas, whereas non-treated tumors with intact
vascularization revealed ﬂuorescence especially at the tumor cen-
ter. Also the macroscopically observed morphology of PDT-treated
tumors shows that therapy may stimulate tumor growth at the
periphery. The vascularization and thus the perfusion in the tumor
become altered after therapy as evident in the inhomogeneous
distribution of the avb3 integrin targeting probe in the tumors. This
heterogeneous distribution reﬂects a partially poor perfusion
which can lead to hypoxia and acidosis, both known to promotedifferent aspects of carcinogenesis, like induction of chromosomal
strand breaks or metastasis, increased resistance to anticancer
therapies, the development of a more aggressive tumor phenotype
and the induction of proangiogenic factors [36]. Therefore, partic-
ular attention should be devoted to the treatment plan or multiple
treatments should be organized to avoid these incidents [32]. The
reason for the presence of suboptimal treated regions at the outer
tumor range is unknown and might be ascribed to the inhomoge-
neous distribution of Foslip [37] or a non-uniform laser illumi-
nation of the tumor area.
The biodistribution data of DY-734-annexin V 5 days after PDT
and 3 days after application showed the highest ﬂuorescence sig-
nals in the kidneys and lower signals in the liver. This bio-
distribution pattern is similar to that found for 99mTc labeled
annexin V [9,38]. This implies that regardless of which dye or
radionuclide is coupled to annexin V, the biodistribution of the
probe remains almost unaltered. The observed kidney and liver
ﬂuorescence signals illustrate the fast renal excretion of the optical
probe, suggesting a nonspeciﬁc uptake by the proximal renal tubule
cells, which has been shown to be a typical event for low-molecular-
weight proteins [9,38]. It also implies a rapid blood clearance.
The half-life of annexin V after intravenous injection is known to
be less than 7 min [23,39,40]. Due to the high afﬁnity (KD ¼ 20 nM)
and high speciﬁcity (reduction of ﬂuorescence around 89% in a
blocking experiment), our DY-734-annexin V probe was still able to
efﬁciently and speciﬁcally detect the therapeutic efﬁcacy of PDTat 2
days after treatment as our in vivo imaging data show.
The comparatively low ﬂuorescence signals in the liver peaked
at 8 days after DY-734-annexin V injection. This ﬁnding can be
attributed to ﬂuorescence labeled apoptotic cells, which are
removed out of the tumor by phagocytic macrophages [23] and
transferred to the liver. On the other hand, it also suggests that the
ﬂuorescence signals are due to probe degradation processes, which
lead to the accumulation of the hydrophilic dye in the kidney and
liver [41]. The reason for the higher accumulation of the annexin
probe or free dye in the liver of non-PDT-treated compared to PDT-
treated animals is not clear. Presumably, the systemic injection of
the photosensitizing agentmodiﬁes distinct functions in the liver. A
systemic effect of PDT of tumors (i.e. use of photosensitizer and
laser light) is unlikely since the photosensitizer is selectively acti-
vated at the tumor area. In this context, DY-734 Fab fragments were
also shown to be accumulated in the kidney in contrast to the
whole antibody counterparts, which demonstrates the particular
renal elimination of low-molecular-weight probes [42]. Addition-
ally the hydrophilic properties of DY-734 imply a low afﬁnity for
plasma proteins, which further promotes renal excretion.
The biodistribution of the avb3 integrin targeting probe showed
the highest ﬂuorescence signal in the tumors and thus a speciﬁc
detection of the tumor vascularization via binding to integrins.
Fluorescence signals of the kidneys reﬂect the renal excretion of
this small peptide. On the other hand, a cleavage of the IRDye
800CW from the RGD-peptide could be responsible for the probe
accumulation in the kidneys [35].
Our data show that multiplexed ﬂuorescence optical imaging
offers the possibility of a simultaneous detection of several targets
by using different spectroscopic properties of the used probes. This
allows us to distinctly monitor the molecular changes that result
due to therapy. Considering the limited penetration depth of light
into tissues, the application of the proposed methodology is
restricted to pathologies being easily accessible to light.
5. Conclusion
In summary, we demonstrated the feasibility of a multiplexed
approach for the detection of the therapeutic efﬁcacy of PDT by
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apoptosis with annexin V and the tumor vascularization. We show
that the detection of PDT-based apoptosis induction is feasible at
least 2 days after treatment. Furthermore, we demonstrated that to
avoid false negative ﬁndings, the inclusion of a second probe tar-
geting the tumor vasculature is indispensable. Taken together, our
observations provide new insights into tumor response to PDT as
well as into the mechanisms of therapy monitoring.Acknowledgments
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